Latest news with #enVistaEnvy
Business Wire
08-05-2025
- Business
- Business Wire
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Bausch + Lomb Corporation ('BLCO' or the 'Company') (NYSE: BLCO) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAUSCH + LOMB CORPORATION (BLCO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On March 27, 2025, BLCO disclosed that it had '[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs)' and was voluntarily recalling all of its enVista Envy and enVista Aspire IOLs, as well as enVista monofocal lenses. On this news, BLCO's stock price fell $1.54, or 9.8%, over two consecutive trading days to close at $14.13 per share on March 28, 2025, thereby injuring investors. Then, on April 30, 2025, BLCO released its first quarter 2025 financial results, disclosing that 'as enVista ramps back up, for the full year 2025, [it] estimate[s] one-time recall headwinds of approximately $55 million to revenue and $65 million to adjusted EBITDA.' On this news, BLCO's stock price fell $2.16, or 15.7%, to close at $11.56 per share on April 30, 2025, thereby injuring investors further. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding BLCO should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
08-05-2025
- Business
- Business Wire
Bausch + Lomb Corporation (BLCO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Bausch + Lomb Corporation ('BLCO' or the 'Company') (NYSE: BLCO) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BAUSCH + LOMB CORPORATION (BLCO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On March 27, 2025, BLCO disclosed that it had '[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs)' and was voluntarily recalling all of its enVista Envy and enVista Aspire IOLs, as well as enVista monofocal lenses. On this news, BLCO's stock price fell $1.54, or 9.8%, over two consecutive trading days to close at $14.13 per share on March 28, 2025, thereby injuring investors. Then, on April 30, 2025, BLCO released its first quarter 2025 financial results, disclosing that 'as enVista ramps back up, for the full year 2025, [it] estimate[s] one-time recall headwinds of approximately $55 million to revenue and $65 million to adjusted EBITDA.' On this news, BLCO's stock price fell $2.16, or 15.7%, to close at $11.56 per share on April 30, 2025, thereby injuring investors further. Contact Us To Participate or Learn More: If you purchased BLCO securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
08-05-2025
- Business
- Business Wire
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces an investigation of Bausch + Lomb Corporation ('BLCO' or the 'Company') (NYSE: BLCO) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAUSCH + LOMB CORPORATION (BLCO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is the Investigation About? On March 27, 2025, BLCO disclosed that it had '[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs)' and was voluntarily recalling all of its enVista Envy and enVista Aspire IOLs, as well as enVista monofocal lenses. On this news, BLCO's stock price fell $1.54, or 9.8%, over two consecutive trading days to close at $14.13 per share on March 28, 2025, thereby injuring investors. Then, on April 30, 2025, BLCO released its first quarter 2025 financial results, disclosing that 'as enVista ramps back up, for the full year 2025, [it] estimate[s] one-time recall headwinds of approximately $55 million to revenue and $65 million to adjusted EBITDA.' On this news, BLCO's stock price fell $2.16, or 15.7%, to close at $11.56 per share on April 30, 2025, thereby injuring investors further. Contact Us to Participate or Learn More: If you purchased BLCO securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Century City, California 90067 Call us at: 310-914-5007 Email us at: info@ Visit our website at: Follow us for updates on Twitter at If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
USA Today
11-04-2025
- Business
- USA Today
Bausch + Lomb recalls lenses used in cataract surgery due to inflammatory reactions
Bausch + Lomb recalls lenses used in cataract surgery due to inflammatory reactions Bausch + Lomb has recalled lenses used during cataract surgery due to complications when the lenses are used, according to an announcement from the Canada-based eyecare company posted on the U.S. Food and Drug Administration's website. The company recalled all lots of its enVista Aspire, enVista Aspire Toric, enVista Envy and enVista Envy Toric intraocular lenses. Also included are the enVista monofocal and enVista monofocal Toric lenses, the company said. The company recalled the products after receiving an increased number of reports of toxic anterior segment syndrome (TASS), an inflammatory reaction of the anterior segment of the eye. 'This action was taken after the company received reports of complications, the cause of which could not immediately be explained,' Bausch + Lomb said in its announcement. Brent Saunders, chairman and CEO, Bausch + Lomb, said in the announcement that patient safety is the company's main concern. 'Surgeons and patients trust Bausch + Lomb, and I believe that this voluntary recall is the best thing we can do to honor that trust,' Saunders said. Read more: USA TODAY's recall database What is an intraocular lens? An intraocular lens, also called an IOL, is a small, artificial lens doctors surgically add to the eye. Doctors remove the eye's natural lens during surgery and then replace it with the intraocular lens, according to the American Academy of Ophthalmology. The lens bends light rays that enter the eye, helping patients to see, the academy said. The natural lenses are clear but those suffering from cataracts have cloudy lenses. The cloudiness causes patients to have blurry, hazy or less colorful vision. Doctors who treat these patients remove the cloudy lenses and replace them with the clear intraocular lenses like the ones Bausch + Lomb manufactures. The intraocular lenses are made of silicone, acrylic, or other plastics and are coated in material to protect the eyes from the sun's ultraviolet rays. Similar to prescription glasses and contact lenses, intraocular lenses come in different strengths, the academy said. According to the academy, intraocular lenses function in different ways to address a range of vision issues. What lenses are recalled? Recalled lenses include: enVista Monofocal – All models starting with EE enVista Aspire IOL – All models starting with EA enVista Envy IOL – All models starting with EN enVista Monofocal Toric IOL – All models starting with ETE enVista Aspire Toric IOL – All models starting with ETA enVista Envy Toric IOL – All models starting with ETN What is toxic anterior segment syndrome? Bausch + Lomb issued the recall after it received reports of toxic anterior segment syndrome, also called TASS, according to the announcement. TASS is a complication in cataract surgeries that involves an inflammatory reaction inside the eye. The complication typically occurs 12 to 48 hours after eye surgery, the company said. The condition can be caused by detergents or disinfectants on surgical instruments, improperly mixed solutions, preservatives-containing medications injected into the eye, or endotoxins in intraocular lens implants, the company said. According to the company, all enVista TASS cases reported to Bausch + Lomb were treated quickly and improved. None of these cases led to the lenses having to be removed. 'These reports represent only 1-2% of implanted lenses, with a positive prognosis for everyone involved,' Saunders said. 'We look forward to identifying a root cause and bringing the enVista platform back to market.' What should I do if I am having complications? The company said it is already communicating with eyecare professionals and recommends that they keep an eye on cataract surgery patients for at least 48 hours after surgery. Patients who are having complications should contact their doctors immediately. To report issues, contact Bausch + Lomb Customer Service at 1-800-338-2020, option 1, or submit a report to FDA's MedWatch program. Saleen Martin is a reporter on USA TODAY's NOW team. She is from Norfolk, Virginia – the 757. Email her at sdmartin@
Yahoo
29-03-2025
- Business
- Yahoo
Bausch + Lomb Stock Sinks on 'Voluntary Recall' of Some Implantable Eye Lenses
Bausch + Lomb shares tumbled in intraday trading Friday, a day after the eye-care company announced a "voluntary recall" of some of its intraocular lenses due to safety concerns. On Thursday, Bausch + Lomb said it was recalling its enVista Aspire and enVista Envy lenses and also some enVista monofocal lenses in the U.S. after the company received an increased number of reports of toxic anterior segment syndrome (TASS) caused by the lenses. Shares of Bausch + Lomb are off nearly 5% in Friday afternoon trading and have lost about 17% of their value in the past + Lomb (BLCO) shares tumbled in intraday trading Friday, a day after the eye-care company announced a "voluntary recall" of some of its intraocular lenses due to safety concerns. On Thursday, Bausch + Lomb said it was recalling its enVista Aspire and enVista Envy lenses and some enVista monofocal lenses in the U.S. after the company received an increased number of reports of toxic anterior segment syndrome (TASS) caused by the lenses. The company announced the recall 'out of an abundance of caution' and noted that it couldn't immediately explain the causes for the complications. Intraocular lenses, or IOLs, are artificial lenses implanted in the eye during cataract surgery to replace the natural lens and are aimed at improving vision. TASS, an inflammatory reaction inside the eye, is 'a potential complication in any cataract surgery' and typically appears between 12 and 48 hours after eye surgery, Bausch + Lomb said. Shares of Bausch + Lomb are down almost 5% in intraday trading Friday and have lost about 17% of their value in the past year. Read the original article on Investopedia Sign in to access your portfolio
